Skip to content
RAPPRapport Therapeutics, Inc.

Earnings

When Rapport Therapeutics, Inc. reports, what it reported each quarter, and how the stock took the results.

15 quarters. Mar 31, 2023 to Sep 30, 2026. USD.

Next results · Q4 2026Projected

Mar 9, before the open

Tue, Mar 9, 2027in 111 days

Projected from its last 8 releases. The company has not named the day yet.

Quarter
Q4 2026 · Ends about Dec 31, 2026
10-K window
Mar 3 – 18

Read against Q4 2025

The same quarter a year earlier, the figures the next ones will be compared with. Thaler holds no estimates.

Revenue
—
Revenue, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m
Net income
-$33.76M
Net income, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q4 2025 n/m
EPS
—
EPS, change from a year earlier: Q3 2026 n/m, Q2 2026 n/m, Q1 2026 n/m, Q3 2025 n/m

Quarter by quarter

Q3 2026$0.00No Q3 2025 on file

Latest results

  1. Q3 2026Nov 4, 2026, before the openThe release
    Revenue
    $0.00
    —
    Net income
    -$40.24M
    N/M
    EPS
    -$0.84
    N/M
    On October 20, 2026, the Company reported topline results from its randomized, double-blind, placebo-controlled Phase 2 trial of RAP-219 in adults with bipolar I disorder (BD) (N=253) experiencing an acute manic episode.
  2. Q2 2026Aug 5, 2026, before the openThe release+0.9%by the close of Aug 5
    Revenue
    $0.00
    —
    Net income
    -$56.62M
    N/M
    EPS
    -$1.19
    N/M
  3. Q1 2026May 7, 2026, before the openThe release+7.7%by the close of May 7
    Revenue
    $20.00M
    —
    Net income
    -$19.86M
    N/M
    EPS
    -$0.42
    N/M
  4. Q4 2025Mar 10, 2026, before the openThe release2.9%by the close of Mar 10
    Revenue
    —
    —
    Net income
    -$33.76M
    N/M
    EPS
    —
    —

All quarters

PeriodEndedAnnouncedFiledLagFormRevenueΔ yoyEPS dil.MoveSource trail
FY 2026
Q3 2026Sep 30, 2026Nov 4, 2026 · pre-marketNov 4, 202635 d10-Q$0.00—-$0.84—
Q2 2026Jun 30, 2026Aug 5, 2026 · pre-marketAug 5, 202636 d10-Q$0.00—-$1.19+0.9%
Q1 2026Mar 31, 2026May 7, 2026 · pre-marketMay 7, 202637 d10-Q$20.00M—-$0.42+7.7%
FY 2025
Q4 2025derivedDec 31, 2025Mar 10, 2026 · pre-marketMar 10, 202669 d10-K———2.9%
Q3 2025Sep 30, 2025Nov 6, 2025 · pre-marketNov 6, 202537 d10-Q$0.00—-$0.713.2%
Q2 2025Jun 30, 2025Aug 7, 2025 · pre-marketAug 7, 202538 d10-Q$0.00—-$0.75+5.5%
Q1 2025Mar 31, 2025May 8, 2025 · pre-marketMay 8, 202538 d10-Q$0.00—-$0.68+3.6%
FY 2024
Q4 2024derivedDec 31, 2024Mar 11, 2025 · pre-marketMar 11, 202570 d10-K———+8.3%
Q3 2024Sep 30, 2024Nov 7, 2024 · pre-marketNov 7, 202438 d10-Q——-$0.50+2.9%
Q2 2024Jun 30, 2024Aug 8, 2024 · pre-marketAug 8, 202439 d10-Q——-$1.7012.3%
Q1 2024Mar 31, 2024——————-$11.07—
Earlier years, FY 2023 to FY 2023

Move: the stock from the last close before the release to the first close after it. Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.

Source filings

10-QNov 4, 2026446217
10-QAug 5, 2026333862
10-QMay 7, 2026210355
10-KMar 10, 2026099360
10-QNov 6, 2025268096
10-QAug 7, 2025104565
10-QMay 8, 2025066393
10-KMar 11, 2025036828
10-QNov 7, 2024122801
10-QAug 8, 2024093334

Provenance

ProvenanceData status and checks

Rapport Therapeutics, Inc. · CIK 2012593 · Engraved from SEC EDGAR